Whalesbook
📉 The Financial Deep Dive
Zenlabs Ethica Limited has announced its unaudited standalone financial results for the quarter and nine months ended December 31, 2025, revealing significant financial distress and a forced business model pivot.
The Numbers:
For the third quarter of fiscal year 2026 (Q3 FY26), revenue from operations stood at ₹1,242.78 Lakhs, marking a 2.3% decrease from ₹1,272.29 Lakhs in Q3 FY25. The company registered a substantial net loss of ₹200.76 Lakhs for the quarter, a stark contrast to the profit of ₹8.51 Lakhs reported in the corresponding period last year. The basic and diluted Earnings Per Share (EPS) for Q3 FY26 was ₹(3.08).
Across the nine-month period ended December 31, 2025, revenue from operations declined by 5.5% YoY to ₹3,633.84 Lakhs, down from ₹3,843.71 Lakhs in the prior year. The net loss for the nine months widened significantly to ₹193.67 Lakhs, compared to a profit of ₹17.86 Lakhs in the same period last year. The nine-month EPS stood at ₹(2.98).
The Quality & Exceptional Impact:
The company's profitability has been severely impacted by an exceptional item charge of ₹207.81 Lakhs recognized during Q3 FY26. This charge arose directly from the Reserve Bank of India's (RBI) order dated November 7, 2025, which cancelled Zenlabs Ethica's NBFC registration. Consequently, the company is no longer permitted to conduct NBFC activities and has had to dispose of and write off investments, loans, and advances inconsistent with its current operations. This substantial one-off cost heavily skewed the profit before tax and net profit figures.
The Grill:
The central point of contention and strategic shift is the RBI's cancellation of Zenlabs Ethica's NBFC registration. This regulatory action has fundamentally altered the company's operational scope, forcing a complete divestment from its non-banking financial activities. Management's strategy is now exclusively focused on its existing business of trading pharmaceutical formulations, as NBFC operations are no longer permissible. The company also noted the appointment of Mr. Amit Kumar as Company Secretary & Compliance Officer and took note of Ms. Manju Bala's resignation from the same role.
Risks & Outlook:
- Specific Risks: The primary risk is the company's ability to sustain and grow profitability solely through its pharmaceutical trading operations, without the diversified income streams from NBFC activities. The financial impact of the ₹20.78 crore write-off needs to be absorbed. Regulatory compliance post-NBFC license cancellation is critical.
- The Forward View: Investors will closely monitor Zenlabs Ethica's performance in the pharmaceutical trading segment in the upcoming quarters. The success of its revised business model and its capacity to generate consistent profits will be key determinants of its future valuation. The company's ability to adapt and thrive within its narrowed operational focus remains the most significant factor to watch.